Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03015207 · ClinicalTrials.gov registry record · Phase 1
First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or Obesity
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT03015207 is a Phase 1 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 56 participants.
The verdict
NCT03015207, a Phase 1 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
This trial is conducted in The United States of America. The aim of this trial is to investigate Safety, Tolerability and Pharmacokinetics (the exposure of the trial drug in the body) of NNC0194-0499 in Male Subjects with Overweight or Obesity.
Interventions
- DRUG Placebo
- DRUG NNC0194-0499
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2017-01-06 |
| Est. Completion | 2017-10-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03015207
The ClinicalTrials.gov registry entry for NCT03015207 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03015207 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03015207 about?
NCT03015207 is a clinical study titled "First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or Obesity". This trial is conducted in The United States of America. The aim of this trial is to investigate Safety, Tolerability and Pharmacokinetics (the exposure of the trial drug in the body) of NNC0194-0499 in Male Subjects with Overweight or Obesity.
What is the current status of trial NCT03015207?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2017-01-06. Estimated completion is 2017-10-26.
What interventions are being tested in trial NCT03015207?
The interventions under investigation include: Placebo (DRUG), NNC0194-0499 (DRUG).
Who is sponsoring clinical trial NCT03015207?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.